Sign in
URGN Stock Price, Chart, Stats & News
UroGen Pharma Ltd.
Save
1.64B
Market cap
–
Current P/E
–
Forward P/E
URGN chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 88.66% |
Operating margin | -113.73% |
Pretax margin | -139.74% |
Net margin | -139.81% |
Effective tax rate | -0.05% |
ROA | -76.57% |
ROE | 170.21% |
D/E | -1.22x |
Interest coverage ratio | -3.69x |
URGN valuation
P/E | – |
P/S | 7.61x |
P/B | -8.01x |
P/CF | -5.20x |
P/FCF | -5.14x |
P/OCF | -5.20x |
PEG | -0.73x |
EV multiple | -6.03x |
About
UroGen Pharma Ltd. is a biotechnology firm dedicated to creating and marketing innovative treatments for specialized cancers and diseases affecting the urinary tract. Its proprietary technology includes RTGel, a biocompatible polymer with reverse thermal gelation properties designed to enhance the efficacy of existing medications. The company also markets Jelmyto, used in pyelocalyceal solutions.
Similar securities
Based on sector and market capitalization
Report issue